Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03102632 · ClinicalTrials.gov registry record · NA
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
A NA study of Autosomal Dominant Polycystic Kidney, sponsored by The Rogosin Institute.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03102632: Completed NA study of Autosomal Dominant Polycystic Kidney, sponsored by The Rogosin Institute.
NCT03102632 is a NA study of Autosomal Dominant Polycystic Kidney that has completed, run by The Rogosin Institute. The registered enrollment target is 10 participants, below the 103-participant average among 6 other Autosomal Dominant Polycystic Kidney trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03102632, a NA study of Autosomal Dominant Polycystic Kidney, has completed, sponsored by The Rogosin Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients affected by Autosomal Dominant Polycystic Kidney Disease (ADPKD) need a safe and effective long-term treatment regimen. Unfortunately, there are still no disease-specific treatment for ADPKD approved in the US. A rational step towards identifying such agents is to test therapies that have a proven safety profile with mechanisms of action that can counter the disease progression. The purpose of this study is to investigate whether drinking increased amounts of water (water loading) might slow down polycystic kidney growth or kidney function decline. Water loading can cause the suppression of a pathway that causes fluid buildup and cyst growth. High water intake has been safely used in the clinical setting, such as in the case of kidney stone therapy. New York State tap water is widely available and safe, making it highly cost-effective as well.
Primary Outcome
Total kidney volumes will be measured before and after the period of high water intake. Kidney volume growth with high water intake will be compared to baseline kidney volume growth.
Conditions Studied
Interventions
- OTHER High Water Intake
Study Locations (1)
New York
- The Rogosin Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2021-12-31 |
| Phase | NA |
What the finished NCT03102632 record still lists
NCT03102632 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 103-participant average among 6 other Autosomal Dominant Polycystic Kidney trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney appearing as the primary indexed condition, and to 1 intervention - of which High Water Intake is the first listed.
NCT03102632 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03102632 about?
NCT03102632 is a clinical study titled "A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease". Patients affected by Autosomal Dominant Polycystic Kidney Disease (ADPKD) need a safe and effective long-term treatment regimen. Unfortunately, there are still no disease-specific treatment for ADPKD approved in the US. A rational step towards identifying such agents is to test therapies that have a...
What is the current status of trial NCT03102632?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2017-06-01. Estimated completion is 2021-12-31.
What conditions does trial NCT03102632 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney.
What interventions are being tested in trial NCT03102632?
The interventions under investigation include: High Water Intake (OTHER).
Who is sponsoring clinical trial NCT03102632?
This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03102632 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD
ACTIVE NOT RECRUITING · NA
-
Daily Caloric Restriction in ADPKD
ACTIVE NOT RECRUITING · NA
-
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
RECRUITING · Phase 2
-
A Prospective Observational Study of Foam Sclerotherapy .
RECRUITING
-
Statin Therapy in Patients With Early Stage ADPKD
ACTIVE NOT RECRUITING · Phase 4
-
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI